KAG-308

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555556

CAS#: 1215192-68-9

Description: KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration.


Chemical Structure

img
KAG-308
CAS# 1215192-68-9

Theoretical Analysis

MedKoo Cat#: 555556
Name: KAG-308
CAS#: 1215192-68-9
Chemical Formula: C24H30F2N4O3
Exact Mass: 460.2286
Molecular Weight: 460.5258
Elemental Analysis: C, 62.59; H, 6.57; F, 8.25; N, 12.17; O, 10.42

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: KAG-308; KAG 308; KAG308;

IUPAC/Chemical Name: 4-[(Z)-(1S,5R,6R,7R)-6-[(1E,3R,4R)-3-Hydroxy-4-(m-tolyl)-1-pentenyl]-7-hydroxy-4,4-difluoro-2-oxabicyclo[3.3.0]octan-3-ylidene]-1-(tetrazol-5-yl)butane

InChi Key: KSELABKNBIUMGG-YGBAREPYSA-N

InChi Code: InChI=1S/C24H30F2N4O3/c1-14-6-5-7-16(12-14)15(2)18(31)11-10-17-19(32)13-20-23(17)24(25,26)21(33-20)8-3-4-9-22-27-29-30-28-22/h5-8,10-12,15,17-20,23,31-32H,3-4,9,13H2,1-2H3,(H,27,28,29,30)/b11-10+,21-8-/t15-,17+,18-,19-,20+,23-/m1/s1

SMILES Code: FC1(F)/C(O[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)[C@@H](C3=CC=CC(C)=C3)C)[C@@]12[H])=C/CCCC4=NN=NN4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 460.5258 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nishimura R, Shirasaki T, Tsuchiya K, Miyake Y, Watanabe Y, Hibiya S, Watanabe
S, Nakamura T, Watanabe M. Establishment of a system to evaluate the therapeutic
effect and the dynamics of an investigational drug on ulcerative colitis using
human colonic organoids. J Gastroenterol. 2019 Jan 1. doi:
10.1007/s00535-018-01540-y. [Epub ahead of print] PubMed PMID: 30599053.

2: Toyoda Y, Morimoto K, Suno R, Horita S, Yamashita K, Hirata K, Sekiguchi Y,
Yasuda S, Shiroishi M, Shimizu T, Urushibata Y, Kajiwara Y, Inazumi T, Hotta Y,
Asada H, Nakane T, Shiimura Y, Nakagita T, Tsuge K, Yoshida S, Kuribara T, Hosoya
T, Sugimoto Y, Nomura N, Sato M, Hirokawa T, Kinoshita M, Murata T, Takayama K,
Yamamoto M, Narumiya S, Iwata S, Kobayashi T. Ligand binding to human
prostaglandin E receptor EP(4) at the lipid-bilayer interface. Nat Chem Biol.
2019 Jan;15(1):18-26. doi: 10.1038/s41589-018-0131-3. Epub 2018 Dec 3. PubMed
PMID: 30510193.

3: Watanabe Y, Murata T, Amakawa M, Miyake Y, Handa T, Konishi K, Matsumura Y,
Tanaka T, Takeuchi K. KAG-308, a newly-identified EP4-selective agonist shows
efficacy for treating ulcerative colitis and can bring about lower risk of
colorectal carcinogenesis by oral administration. Eur J Pharmacol. 2015 May
5;754:179-89. doi: 10.1016/j.ejphar.2015.02.021. Epub 2015 Feb 19. PubMed PMID:
25704618.



Additional Information

Agonists for EP4 receptor, a prostaglandin E2 receptor subtype, appear to be a promising therapeutic strategy for ulcerative colitis (UC) due to their anti-inflammatory and epithelial regeneration activities.